Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.146
Buy
RSI(14)
55.168
Neutral
STOCH(KDJ)(9,3,3)
44.439
Sell
ATR(14)
4.415
High Vlolatility
CCI(14)
27.975
Neutral
Williams %R
59.347
Sell
TRIX(12,20)
0.480
Sell
StochRSI(14)
0.000
Oversold
Search
Incyte Corp
INCYAdd to Watchlist
119.470USD
-3.520-2.86%
Close 07-31 16:00（ET）Quotes delayed by 15 min
23.89BMarket Cap
16.37P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.86%
5 Days
+1.53%
1 Month
+5.39%
6 Months
+19.39%
Year to Date
+20.96%
1 Year
+59.53%
Key Figures
122.190Open
122.670High
1.83MVolume
16.37P/E TTM
13.00P/E Dynamic
--Dividend TTM
0.92%Turnover Ratio
122.990Prev. Close
118.440Low
174.09MTurnover
732.42P/E Static
4.25P/B
0.00%Div Yield TTM
21.88%ROA
112.29052wk High
0.59Volume Ratio
32.62MNet Profit
199.95MShares
7.2963EPS TTM
0.79Beta
30.82%ROE
63.92552wk Low
3.44%Amplitude
93.73%Gross Margin
23.89BMarket Cap
2.85Reward/Risk
1.84%Risk Rate
TradingKey Stock Score of Incyte Corp
Currency: USD Updated: 2026-07-31Key Insights
Incyte Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 122.34.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incyte Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Incyte Corp Highlights
StrengthsRisks
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.12% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.14B.
Undervalued
The company’s latest PE is 16.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 209.33M shares, decreasing 1.76% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 30.41K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
122.339
Target Price
-3.75%
Upside Space
Incyte Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
27
analysts
Buy
Current Rating
122.339
Target Price
-3.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Incyte Corp
INCY
27
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
123.682
Sell
MA10
120.160
Sell
MA20
118.293
Buy
MA50
109.133
Buy
MA100
102.241
Buy
MA200
101.258
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Incyte Corp Info
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Ticker SymbolINCY
CompanyIncyte Corp
CEOMeury (Bill)
Websitehttps://www.incyte.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Incyte Corp (INCY)?
The current price of Incyte Corp (INCY) is 119.47.
What is the symbol of Incyte Corp?
The ticker symbol of Incyte Corp is INCY.
What is the 52-week high of Incyte Corp?
The 52-week high of Incyte Corp is 112.29.
What is the 52-week low of Incyte Corp?
The 52-week low of Incyte Corp is 63.92.
What is the market capitalization of Incyte Corp?
The market capitalization of Incyte Corp is 23.89B.
Is Incyte Corp (INCY) currently rated as Buy, Hold, or Sell?
According to analysts, Incyte Corp (INCY) has an overall rating of Buy, with a price target of 122.34.
What is the Earnings Per Share (EPS TTM) of Incyte Corp (INCY)?
The Earnings Per Share (EPS TTM) of Incyte Corp (INCY) is 6.59.